ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas.
| |
| [28-September-2023] |
| IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies HOUSTON, Sept. 28, 2023 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy. The Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) consists of a dose escalation and expansion portion to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. Anticipated tumor types in the dose escalation portion of the study include ovarian, colorectal and triple-negative breast cancer. “Many tumors are not responsive to the current immunotherapies, representing a significant unmet need,” said ImmunoGenesis President and CEO James Barlow. “Our vision is to unlock the potential of immunotherapy for a broader group of patients by targeting key mechanisms of immune resistance. We believe that this study will deliver initial proof of concept for our groundbreaking multitasking approach of using a single molecule to address immunosuppression and PD-1 pathway blockade.” “PD-L1 and PD-L2 are widely expressed not only on various tumors but also on immunosuppressive cells in the tumor microenvironment,” said ImmunoGenesis Acting Chief Medical Officer Dr. Jeremy Barton. “IMGS-001 is designed to remove these immunosuppressive cells and potentially improve PD-1 pathway blockade. This Phase 1a/1b clinical trial is an important first step towards validating this approach as potentially effective in treating cold, immune-excluded cancers.” About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor About ImmunoGenesis Contacts ImmunoGenesis Investors: Media:
SOURCE ImmunoGenesis |
View original content:
